Oticara's Intranasal Steroid Cream Achieves Phase 2 Success in Post-Surgical Chronic Rhinosinusitis

Oticara's intranasal steroid cream met primary endpoints in a phase 2 trial for post-surgical chronic rhinosinusitis (CRS), showing significant improvements in 4CSS and SNOT-22 scores by week 3. The in-office treatment provided rapid, durable symptom relief and was well-tolerated, with no severe adverse events reported.

The late-breaking presentation, delivered by Professor Anders Cervin, MD, PhD, FRACS, will highlight findings from the Phase 2 trial of Oticara’s proprietary nasal-mucosa-optimized steroid cream. The treatment is an Ear, Nose and Throat (ENT) physician-administered cream designed specifically for the nasal mucosa, with clinical data demonstrating single-dose, durable relief for hard-to-treat post-surgical CRS patients.

“We are honored to have been selected to present our recent clinical study results at AAO-HNSF,” said Chris Marich, Founder and Chief Executive Officer of Oticara. “We see a clear need for new options that can deliver durable benefits and reduce reliance on systemic steroids in hard-to-treat CRS patients with an easy-to-administer single-dose treatment.”

Full data from the Phase 2 OT-007B trial will be presented during the meeting and the scientific paper is undergoing peer review by the American Academy of Otolaryngology–Head and Neck Surgery Foundation.